GlassScriptPhysician profile
Christopher I Obeime
NPI 1659480697
$906,879.79
in general payments reported to CMS, 2019-2025
39 companies · $210K in 2025
The $210K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101K · 2020: $32K · 2021: $27K · 2022: $149K · 2023: $182K · 2024: $205K · 2025: $210K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $496K · Travel and Lodging: $35K · Consulting Fee: $33K · Food and Beverage: $26K · Honoraria: $6,860 · Education: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $495,947.78 |
| Travel and Lodging | $35,450.06 |
| Consulting Fee | $32,763.17 |
| Food and Beverage | $26,476.43 |
| Honoraria | $6,860.08 |
| Education | $494.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $486,530.73 | 2019-2025 | |
| Galderma Laboratories, L.P. | $118,256.04 | 2019-2025 | Aklief, Epsolay, Twyneo |
| Ucb, INC. | $102,449.71 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $51,048.45 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $33,491.16 | 2019-2025 | |
| Dermavant Sciences, INC. | $32,891.42 | 2022-2024 | Vtama |
| Dermira, INC. | $15,340.62 | 2019-2020 | |
| Almirall LLC | $8,737.04 | 2019-2025 | Klisyri |
| Organon LLC | $8,522.98 | 2025 | Vtama |
| Janssen Biotech, INC. | $7,907.53 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $7,631.49 | 2019-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $6,087.34 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $6,021.77 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $5,779.70 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $3,656.11 | 2019-2025 | Taltz, Olumiant, Ebglyss |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Obeime listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.